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Introduction: Identifying issues of importance for patients with 
lung cancer is critical in individualizing care and developing effec-
tive quality of life instruments based on evidence. This study was 
conducted to provide enhanced content validity for measures assess-
ing quality of life and patient-reported outcomes (PROs).
Methods: We conducted an anonymous, cross-sectional, electronic 
web-based survey of 660 lung cancer patients. The survey asked 
patients to rank 20 quality of life issues on a 5-point scale rang-
ing from “not important at all” to “very important”. Analysis was 
obtained using key factors such as stage of disease, performance sta-
tus, and gender.
Results: The survey was completed by 297 males and 363 females 
(median age 62 years). The top five rated issues were: quality of life, 
maintaining independence, ability to perform normal activities, abil-
ity to sleep, and not being fatigued. The issues of importance were 
all ranked, using the two highest categories (“very important” and 
“important”) by at least 90% of patients. Although symptoms are 
important to patients, they were not the most highly ranked issues of 
concern; instead, global issues illustrating the effect of the symptoms 
on the patient, such as quality of life, maintaining independence, and 
performing normal activities were ranked highest.
Conclusions: This is the largest analysis of evidence-based data 
determining content validity for quality of life and PROs as indi-
cated by patients. These results provide greater confidence that 
the content of lung cancer quality of life measures is appropriate. 
In addition, the survey clearly demonstrates that PRO measures 
that only evaluate symptoms are not fully responding to patient-
expressed needs.
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Identifying key issues for patients with cancer is central to assessing quality of life and patient reported outcomes 
(PROs). Many quality of life and PRO questionnaires are 
available for patients with a variety of diseases and cancers;1 
however, these measures vary in the manner in which the 
developers chose items for inclusion. There has been concern 
that the items utilized in many of these measures may be based 
on limited input from patients. As articulated in the FDA 2009 
guidance for industry document, “…without adequate docu-
mentation of patient input, a PRO instrument’s content valid-
ity is likely to be questioned.”2
As the concept of PROs has become increasingly 
evaluated in oncology, more cancer-specific measures have 
appeared. In lung cancer and thoracic malignancies, only a 
few measures have both published acceptable psychometrics 
and are in widespread usage.3 Although the current project 
was initiated to expand the underpinnings of the frequently 
used measure the Lung Cancer Symptom Scale (LCSS), 
which has a well-recognized psychometric background,3–5 the 
exercise could prove useful for other lung cancer PRO instru-
ments as well.
The findings of this project, producing results reported 
by patients, could provide an evidence-based background for 
amending existing measures or in the development of newer 
instruments. This methodological approach for content valid-
ity is designed to determine which PRO items are most val-
ued by large samples of patients with cancer. The specific aim 
was to determine whether scales that strictly investigate only 
symptoms provide a sufficient picture of PROs, or do patients 
tell us that global PRO items, such as distress from symptoms 
or the impact of symptoms on performing normal activities, 
afford a context that is necessary for an appropriate evaluation 
of symptoms.
MATERIALS AND METHODS
Participants and Data Collection
This methodological study used a cross-sectional, 
computer-assisted survey of lung cancer patients over a 7-day 
period in 2007. The established patient base of the online 
NexCura, Inc. patient information resource was used to survey 
patients with lung cancer. Patients who had previously visited 
the NexCura website (www.nexcura.com), and had registered, 
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were routinely asked whether it is permissible to contact them 
in the future. Invitation e-mails were sent to those patients 
who had lung cancer and who had agreed to allow further 
contact on registration. The invitation outlined the purpose 
of the survey, and that it would be conducted anonymously. 
Those who responded positively were sent the electronic sur-
vey. Responses were fully anonymous; no patient identifier 
was used at any time and participation was elective. Patients 
with either active disease or a history of lung cancer of any 
histological type were invited to be included in the survey. 
Caregivers were excluded from the study. Participants’ consent 
was indicated by each individual’s willingness to complete 
and return the questionnaire. The NexCura website, available 
only in English, attracted primarily a North American follow-
ing. Based on this and prior NexCura-based surveys,6 we esti-
mate that nearly 90% of the respondents were from the United 
States and Canada. Since the completion of this survey, the 
ownership and mission of NexCura has evolved. NexCura was 
initially an independent company, which was then acquired by 
the media firm Thomson-Reuters Corporation, and is now a 
subsidiary of McKesson Corporation. As of this writing, the 
Nexcura website is no longer operational.
Survey Measures
The initial portion of the survey queried the sociodemo-
graphic profile and health-related information of patients in 
ten questions. This included self reporting of age group, time 
since lung cancer diagnosis, stage at diagnosis, performance 
status parameters, recurrence since completion of treatment or 
presence of metastatic lung cancer, type of treatment received, 
and level of education. To estimate Karnofsky performance 
status (KPS), patients were asked to choose among catego-
ries as given by the straightforward definitions of the origi-
nal KPS scale. Based on these responses, patients were then 
placed in the KPS 80–100% group, 60–70% group, or in the 
< 60% group. To identify the current disease stage, patients 
were asked to select among the following four options: “the 
cancer has been completely removed surgically, or is in com-
plete remission (no sign of cancer on radiograph or tests)”; 
“The cancer is present in my lung or chest but has not spread 
to other organs of the body beyond the chest or lymph nodes 
in the chest”; “The cancer is present in other site(s) or organ(s) 
such as bone, liver, or brain”; or “I do not know.” Based on 
these responses, patients were classified as having “no current 
evidence of disease”, “locally advanced (stage III)” or “meta-
static (stage IV)” disease, respectively.
To provide the survey document to send to patients, a 
panel of 53 oncology professionals who focus on lung cancer 
(i.e., medical oncologists, thoracic surgeons, radiation oncol-
ogists, oncology nurses, and social workers) reviewed the 
literature and existing PRO/quality of life instruments.4,5,7,8 
Based on this review and their experiences, the panel then 
selected the items that were felt to be of the greatest impor-
tance, to submit to patients for their ranking. The group 
voted and selected a total of 20 items for the patient survey. 
The participating patients were also invited to submit items 
which they felt might supplement the survey. The survey 
was then sent to the patients who had responded positively 
to the invitation to participate. These patients ranked each of 
the 20 quality of life/patient reported outcome issues on a 
5-point categorical scale ranging from “not important at all” 
to “very important”. These issues encompassed the physical, 
functional, psychological, social, and spiritual domains of 
quality of life.
Statistical Analysis
All statistical analyses were performed using R 
(Foundation for Statistical Computing, Vienna, Austria).9 
Categorical variables were compared using Pearson’s χ2 tests. 
A p value of less than 0.05 was considered statistically sig-
nificant. p values of post hoc paired comparisons after χ2 tests 
were adjusted with the Bonferroni method.
RESULTS
Demographic Data
Respondents’ demographic profile and cancer charac-
teristics are provided (Table 1). A total of 660 patients com-
pleted the survey (297 males, 363 females, median age 62 
years). Few patients (5%) were unsure of their histologic type 
of lung cancer, whereas 508 patients (77%) reported they had 
non–small-cell lung cancer, and small cell lung cancer was 
reported by 119 patients (18%). The percentages reported of 
the lung cancer histologic types largely match the prevalence 
in the general population. More than half of the patients (60%) 
had stage ≥III disease. Many patients (88%) reported a perfor-
mance status ≥60%.
Quality of Life and PRO Questions
As presented in Table 2, only one of the top five fac-
tors rated as either “very important” or “important” was a 
lung cancer symptom (i.e., fatigue, the fifth highest rated 
item), whereas global issues such as maintaining quality of 
life (96% of patients) and maintaining independence (95%) 
were ranked highest. Patients were invited to submit addi-
tional issues, but only a minority of patients did so. As a 
result, it was judged that none of the submitted items was 
indicated frequently enough to warrant adding an additional 
item to the survey.
Tables 3–5 present the quality of life/PRO survey 
findings stratified by gender, performance status, and can-
cer stage, respectively. There were no survey rating differ-
ences by gender among the top 14 ranked items (Table 3). 
In the lower rated items where differences of more than 5% 
between men and women were seen, women rated anxiety 
(p = 0.04), faith/spiritual concerns (p = 0.003), and issues 
concerning the meaning of life (p = 0.009) somewhat more 
highly than men.
As presented in Table 4, patients reporting a per-
formance status of 80–100% were more likely to rank the 
ability to perform normal activities as an important or very 
important quality of life issue compared with patients with 
a performance status of 60–70% (Bonferroni-adjusted post 
hoc paired comparison p = 0.022) or patients with a perfor-
mance status of <60% (p = 0.027). In addition, patients in 
the highest performance status group (80–100%) were more 
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likely to consider sexual difficulties as an important or very 
important item compared with those with a lower perfor-
mance status (p = 0.048).
The findings by extent of disease for patients with lung 
cancer varied (Table 5). All three disease stage groups ranked 
the ability to perform normal activities at a level of 90% or 
greater. This issue was rated highest by those free of disease 
(96%) and rated lowest those with Stage IV extent (90%). 
Although this difference is of borderline statistical significance 
(p = 0.042), the result is no longer significant when adjusted 
for the multiplicity issue of comparing the three staging 
groups (all Bonferroni-adjusted p values >0.05). Patients hav-
ing locally advanced (stage III) lung cancer were more likely 
to rank shortness of breath as an important or very important 
item compared with patients with metastatic (stage IV) disease 
(p = 0.032). Financial concerns were more important to patients 
without current evidence of disease compared with those with 
stage III disease (p = 0.037). Not having hemoptysis or hoarse-
ness received the highest ranking by those without current evi-
dence of lung cancer compared with those having metastatic 
disease (p = 0.02 and p = 0.0008, respectively).
DISCUSSION
The present report is the largest prospective analysis 
supporting content validity for PRO and quality of life mea-
sures in patients with lung cancer. This method utilized a 
computer-assisted survey approach to obtain patient-reported 
information rapidly from a large patient sample.
The most highly ranked PRO issues were not symp-
toms of lung cancer. Instead, patients ranked such global 
issues (i.e., quality of life, maintaining independence, 
and performing normal activities) highest. Symptoms are 
important to large numbers of patients, but assessing their 
impact on patients is clearly expressed by patients as being 
paramount. Although the number, magnitude, and type of 
symptoms vary from patient to patient, all patients have 
meaningful scores of these three global issues, thus provid-
ing valuable context.
All 20 items were ranked by patients as issues of impor-
tance. Even the lowest ranked item, sexual difficulties, was 
listed as being in the top two categories by nearly half (47%) 
of the patients. The 5-point categorical response scale was use-
ful in that there is a strong separation in the ranking of issues, 
from 96% of patients to 47% when combining the top two 
issues, and 80% to 20% if one examines just the top response 
category, “very important.” Among common symptoms, 
fatigue and pain were ranked highly, whereas hemoptysis, 
TABLE 2.  Importance of Quality of Life Issues Among the 
Study Participants (N = 660)
Ranked as Either  
“Important” or “Very 
Important” a
Ranked 
as “Very 
Important” b
Quality of life 631 (96%) 528 (80%)
Maintaining 
independence
626 (95%) 469 (71%)
Being able to perform 
normal activities
619 (94%) 422 (64%)
Being able to sleep 611 (93%) 416 (63%)
Not being fatigued 603 (91%) 383 (58%)
Not being a burden to others 584 (89%) 429 (65%)
Not having shortness of breath 560 (85%) 383 (58%)
Not having pain 550 (83%) 389 (59%)
Not being depressed 531 (81%) 310 (47%)
Symptom distress 512 (78%) 271 (41%)
Appetite 517 (78%) 218 (33%)
Financial concerns 501 (76%) 290 (44%)
Anxiety 501(76%) 264 (40%)
Hemoptysis 496 (75%) 383 (58%)
Faith/spiritual concerns 425 (64%) 277 (42%)
Cough 416 (63%) 185 (28%)
Hoarseness 413 (63%) 178 (27%)
Problems with urination 412 (62%) 178 (27%)
Meaning of life 401 (61%) 211 (32%)
Sexual difficulties 307 (47%) 132 (20%)
aThis column shows the rankings by the top two categories.
bThis column shows the rankings by the single top category.
TABLE 1.  Demographics of the Study Participants (N = 660)
Gender
Female 365 (55%)
Male 295 (45%)
Age (years) < 45 34 (5%)
45 – 54 145 (22%)
55 – 64 236 (36%) 
(median =62)
65 – 74 180 (27%)
> 74 65 (10%)
Educational level College degree +/−  
graduate degree
224 (34%)
Some college 224 (34%)
High School graduate 165 (25%)
< High School graduate 47 (7%)
Lung cancer histologic type Non–small cell 508 (77%)
Small cell 119 (18%)
Do not know/other 33 (5%)
Performance status 80–100% 290 (44%)
60–70% 290 (44%)
<60% 80 (12%)
Current extent of disease No evidence of  
disease currently
224 (34%)
Locally advanced (stage III) 231 (35%)
Metastatic (stage IV) 165 (25%)
Do not know 40 (6%)
Time since diagnosis 6 months or less 165 (25%)
7–12 months 251 (38%)
1–2 years 159 (24%)
More than 2 years 85 (13%)
Treatment Surgery 350 (53%)
Radiation therapy 416 (63%)
Chemotherapy 561 (85%)
Targeted therapy 238 (36%)
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cough, and hoarseness were ranked considerably lower by 
patients (Table 2).
The classical clinical factors of stage of disease, KPS, 
and gender remain the most important baseline predictors 
of survival in large groups of patients with lung cancer.10 
Although key molecular findings, such as EGFR status,11 are 
prognostic, they identify only small subsets of patients. As 
presented in Tables 3–5, stratification by these three classical 
clinical factors demonstrated that patients ranked the impor-
tance of the PRO issues fairly similarly across all three strata. 
However, some differences were found by strata that deserve 
attention in patient care. Although sexual dysfunction was 
the lowest ranked issue for both genders, men reported this 
issue as important more frequently compared with women. 
On the other hand, women tended to value issues of faith 
and spirituality and concerns about the meaning of life more 
highly compared with men. The ability to perform normal 
activities was more highly ranked among patients with 
higher performance status. It is interesting to note that in 
the current study, lung cancer survivors without current evi-
dence of disease activity were more likely to rank financial 
concerns more highly than patients with metastatic disease. 
Cancer is frequently associated with considerable financial 
stress because of decreased ability to work and of healthcare 
costs.12,13 In summary, these rankings by patients with lung 
cancer could represent a response shift,14,15 perhaps indicat-
ing a change in priorities as health status changes in patients 
confined to their homes or requiring significant assistance 
for their personal needs. For instrument development, this 
also supports consideration of item response theory versus 
classical measurement theory for methodological studies in 
that individual items may be more meaningful than aggre-
gate scores, particularly for stage of disease, gender, and 
performance status.16,17
As with all surveys, there are several limitations 
that should be considered with the present study. In most 
surveys, patients who are too ill seem to be less likely to 
complete the process, particularly those that are computer 
assisted. Although a web-based methodology allows large 
numbers of patients to be surveyed, and to do so rapidly, 
it also requires Internet access and at least some degree of 
computer literacy to participate. In addition, respondents 
in this survey had to have enough interest to seek more 
information about their disease on-line, and then to regis-
ter at the NexCura website. It is unknown for this study if 
sicker or less interested patients or those without computer 
access would or would not share the same views. All data, 
including such demographic data as extent of disease and 
histological type of lung cancer were completely patient 
reported. Patients coming to the Nexcura website had to be 
able to communicate in English, and this website attracted 
largely a North American audience.
The 2007 recommendation by the Mayo/FDA PRO 
Consensus Meeting Group for sufficient evidence for psycho-
metric properties for PROs is a sample of at least 200 cases.16 
In addition, based on the classic validity testing guidelines 
of multiple procedures, sequential use of these procedures, 
and assessment of validity at various stages of instrument 
TABLE 3.  Quality of Life Issues Ranked as Either “Very Important” or “Important” by the Study Participants (N = 660)  
Stratified by Gender
 Male (%; n = 295) Female (%; n = 365) p Value
Quality of life 280 (95%) 351 (96%) 0.43
Maintaining independence 275 (93%) 351 (96%) 0.08
Being able to perform normal activities 276 (94%) 343 (94%) 0.83
Being able to sleep 273 (93%) 338 (93%) 0.98
Not being fatigued 270 (92%) 333 (91%) 0.89
Not being a burden to others 254 (86%) 330 (90%) 0.08
Not having shortness of breath 253 (86%) 307 (84%) 0.56
Not having pain 248 (84%) 302 (83%) 0.65
Not being depressed 232 (79%) 299 (82%) 0.29
Symptom distress 227 (77%) 285 (78%) 0.73
Appetite 239 (81%) 278 (76%) 0.13
Financial concerns 226 (77%) 275 (75%) 0.71
Anxietya 213 (72%) 288 (79%) 0.04
Hemoptysis 220 (75%) 276 (76%) 0.76
Faith/spiritual concernsb 172 (58%) 253 (69%) 0.003
Cougha 177 (60%) 239 (66%) 0.15
Hoarseness 181 (61%) 232 (64%) 0.42
Problems with urination 191 (65%) 221 (61%) 0.27
Meaning of lifeb 163 (55%) 238 (65%) 0.009
Sexual difficultiesa 153 (51%) 154 (42%) 0.01
aIssues that differed by 6–9%, by gender.
bIssues that differed by ≥ 10%, by gender.
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development,18 further support for the content validity of the 
LCSS seemed important. The philosophy behind the devel-
opment of the LCSS was to provide a practical quality of 
life measure that would reduce patient and staff burden in 
serial measurement. At that time, a panel of 52 oncology 
experts (physicians and nurses) and two panels of patients 
(69 with non–small-cell and 52 with small cell lung cancer) 
validated support of the original items, followed by use in 
a large multicenter trial at 25 cancer centers in the United 
States and Canada. For the LCSS, the greatest strengths of 
this on-line survey were the large sample of patients with 
lung cancer (N = 660) and the fact that all rankings were 
self-reported by patients. Members of the expert panel 
(N = 53) for this current content validity study were surprised 
that the ability to sleep was ranked so highly by patients and 
that the global issues (e.g., quality of life, maintaining inde-
pendence, and performing normal activities) were so clearly 
rated as highest in the 20-item survey. It should also be noted 
that the demographic and disease characteristics of the study 
participants (Table 1) are similar to the overall population of 
patients with lung cancer in the United States, supporting the 
generalizability of the results.19
The present study focused on the importance of each 
issue as part of establishing a high level of content valid-
ity for patients with lung cancer. We accordingly aimed to 
determine and report which PRO items were most highly 
valued by our patient population, as these results could affect 
the content of current and future PRO measures. This psy-
chometric testing was based on Anastasi’s (1988) guidance 
that validity should include multiple procedures, a sequen-
tial order for validity testing, and assessment of validity at 
various stages of instrument development.18 Table 2 shows 
that the top two categories of importance included 61% to 
96% of patient responses for all items except one. Although 
patients could choose among all five categories (from very 
important to not important), we believe that reporting 
the top two categories fully revealed the importance that 
patients place on these major issues and that little would be 
gained by illustrating few responses from the lower three 
Likert scale categories.
These findings illustrate several points for PRO and 
quality of life evaluation and address concerns related to 
a previous lack of patient input in PRO instruments.2 The 
results support the content validity of the original LCSS 
items and suggest some additional items, such as maintain-
ing independence and the ability to sleep, that should be 
considered if revised. Moreover, review of these findings 
may be helpful for other PRO measures evaluating lung 
cancer and for those associated with other malignancies. 
As seen in the results of this survey, measures that focus 
only on symptoms and do not include issues related to the 
impact of these symptoms, specifically global or summary 
items, may fail to address PRO issues that are highly valued 
by patients. The web-based approach utilized in this sur-
vey provides a rapid way of obtaining responses from large 
samples of patients to enhance the evaluation of quality of 
life and patient-reported outcomes.
TABLE 4.  Quality of Life Issues Ranked as Either “Very Important” or “Important” by the Study Participants (N = 660) Stratified 
by Performance Status
Performance Status 
80–100 (%; n = 290)
Performance Status 
60–70 (%; n = 290)
Performance status 
<60 (%); n = 80)
p Value (Comparison 
Among All Groups)
Quality of life 281 (97%) 272 (94%) 78 (98%) 0.12
Maintaining independence 280 (96%) 269 (93%) 77 (96%) 0.10
Being able to perform normal activitiesa 281 (97%) 266 (92%) 72 (90%) 0.011
Being able to sleep 273 (94%) 264 (91%) 74 (93%) 0.36
Not being fatigued 268 (92%) 261(90%) 74 (93%) 0.54
Not being a burden to others 258 (89%) 253 (87%) 73 (91%) 0.58
Not having shortness of breath 244 (84%) 246 (85%) 70 (88%) 0.76
Not having paina 238 (82%) 240 (83%) 72 (90%) 0.23
Not being depressed 231 (80%) 232 (80%) 68 (85%) 0.55
Symptom distressa 218 (75%) 226 (78%) 68 (85%) 0.17
Appetitea 222 (77%) 227 (78%) 68 (85%) 0.27
Financial concernsa 224 (77%) 211 (73%) 66 (83%) 0.15
Anxiety 227 (78%) 211 (73%) 63 (79%) 0.25
Hemoptysisa 229 (79%) 209 (72%) 58 (73%) 0.13
Cougha 190 (66%) 178(61%) 48 (60%) 0.49
Faith/spiritual concerns 192 (66%) 182 (63%) 51 (64%) 0.68
Hoarsenessb 191 (66%) 179 (62%) 43 (54%) 0.13
Problems with urination 183 (63%) 178 (61%) 52 (65%) 0.81
Meaning of lifea 189 (65%) 164 (57%) 48 (60%) 0.10
Sexual difficultiesb 152 (52%) 123 (42%) 32 (40%) 0.025
aIssues that differed by 6–9%, by performance status.
bIssues that differed by ≥ 10%, by performance status.
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Not having pain 183 (82%) 193 (84%) 142 (86%) 0.52
Not being depressed 184 (82%) 188 (81%) 129 (78%) 0.59
Symptom distress 175 (78%) 180 (78%) 128 (78%) 0.99
Appetite 178 (80%) 178 (77%) 135 (82%) 0.51
Financial concernsb 183 (82%) 176 (76%) 117 (71%) 0.04
Anxietya 176 (79%) 176 (76%) 121 (73%) 0.48
No hemoptysisb 178 (80%) 179 (78%) 111 (67%) 0.015
Coughb 156 (70%) 151 (65%) 87 (53%) 0.002
Faith/spiritual concerns 147 (66%) 148 (64%) 102 (62%) 0.74
Hoarsenessb 156 (70%) 149 (65%) 85 (52%) 0.001
Problems with urination 141 (63%) 150 (65%) 100 (61%) 0.68
Meaning of life 136 (61%) 142 (62%) 96 (58%) 0.80
Sexual difficultiesb 119 (53%) 104 (45%) 70 (42%) 0.078
aIssues that differed by 6–9%, by extent of disease.
bIssues that differed by ≥ 10%, by extent of disease.
